ALK-positive NSCLC
9 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. (NCT04647110) | Pfizer | 2020-12-14 |
| Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) (NCT04009317) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-08-13 |
| Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib (NCT04056572) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-08-13 |
| The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human (NCT03804541) | Betta Pharmaceuticals Co., Ltd. | 2018-12-28 |
Track ALK-positive NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.